Home›Research›Compare›Semaglutide vs Tirzepatide
Peptide ComparisonSemaglutide vs Tirzepatide
Both are Metabolic peptides.
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
541 providers listed
Semaglutide is carried by more providers on PeptideBase (806 vs 541); otherwise the two are closely matched on the measures we track.
Semaglutide
Half-life
~7 days (once-weekly dosing)
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| More provider options (806 vs 541) | Semaglutide |
| Dual GIP + GLP-1 receptor activation | Tirzepatide |
| Oral formulation available (Rybelsus) | Semaglutide |
| Greater avg. weight loss in phase 3 trials (SURMOUNT vs STEP) | Tirzepatide |
| Longer post-approval safety record (approved 2017 vs 2022) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Semaglutide
Tirzepatide
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Semaglutide
Tirzepatide
Not enough vendor pricing yet.
Where to source these peptides
Semaglutide
806 listed
Browse directory →
Providers offeringTirzepatide
541 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Semaglutide vs Tirzepatide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/semaglutide/tirzepatide